why choose us

First received: July 21, 2023

Clinical Trial: Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Refractory Non-Hodgkin Lymphoma

Study Type: INTERVENTIONAL


Official Title: Phase 1, Open-Label Study of Autologous SIRP?-low Macrophages (SIRPant-M) Administered by Intratumoral Injection Alone or in Combination With Focal External-Beam Radiotherapy in Participants With Rela

Brief Summary: The goal of this study is to test SIRPant-M, an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL).Two dose levels of SIRPant-M are being tested.The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.

Read more